THERAPEUTIC AGENT FOR SCHIZOPHRENIA

• US 20070244147A1
• Filed: 06/25/2007
• Published: 10/18/2007
• Est. Priority Date: 01/08/2003
• Status: Abandoned Application

• Current Assignee: Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group Corp.)
• Original Assignee: Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group Corp.)
• Inventors: TAKASHINA, Ken, BESSHO, Tomoko
• Application Number:
  US11/767,594
• Publication Number:
  US 20070244147A1
• Time in Patent Office: Days
• US Class Current: 514/302
• CPC Class Codes: A61K 31/4741 condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 491/04 Ortho-condensed systems

Abstract

Provision of a pharmaceutical agent useful for the treatment of schizophrenia. As a solving means, a therapeutic agent for schizophrenia containing a 4-acylamino-5,6,7,8-tetrahydrofuro[2,3-b]quinoline derivative, an enantiomer thereof, an acid addition salt thereof or a hydrate or solvate thereof as an active ingredient is provided.

Claims

1. (canceled)

2. A method of treating a condition of schizophrenia in a subject, which method comprises administering to a subject suffering from a condition of schizophrenia an effective amount of a compound of the formula (Ia)

3. The method of claim 2, wherein the compound of the formula (Ia) is a 4-acylamino-5,6,7,8-tetrahydrofuro[2,3-b]quinoline derivative of the formula (Ib)

4. The method of claim 2 wherein the compound of the formula (Ia) is 2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetamide.

6. The method of claim 2, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.

7. The method of claim 3, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.

8. The method of claim 4, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.

5. (canceled)